A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer

MC #23-17

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer

NCT #
NCT05983432
Condition(s)
Non-Small Cell Lung
Molecular Target(s)
EGFR, HER3
Drug Classification(s)
Bispecific Antibodies
Agents(s)
BL-B01D1
Phase(s)
I

Mechanism of Action

BL-B01D1 is an EGFR x HER3 Bispecific

Purpose

  • How much of the study agent can be given with an acceptable level of side effects• The effects of the study agent (good and bad)
  •  How much of the study agent is absorbed into the blood and how fast it is removed
  •  If research tests can be used in the future to predict who will benefit from BL-B01D1
  •  How the study agent is acting on your body

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.